BiotechTube

Encorafenib + Cetuximab + FOLFIRI

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

BRAF V600E

Conditions

BRAF V600E, Metastatic Colorectal Cancer

Trial Timeline

Sep 14, 2021 → Dec 7, 2024

NCT ID
NCT05004350

About Encorafenib + Cetuximab + FOLFIRI

Encorafenib + Cetuximab + FOLFIRI is a phase 2 stage product being developed by Merck for BRAF V600E. The current trial status is completed. This product is registered under clinical trial identifier NCT05004350. Target conditions include BRAF V600E, Metastatic Colorectal Cancer.

What happened to similar drugs?

0 of 2 similar drugs in BRAF V600E were approved

Approved (0) Terminated (1) Active (1)
🔄Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-FluorouracilOno PharmaceuticalPhase 3
❌Cobimetinib + Atezolizumab + PembrolizumabRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05004350Phase 2Completed

Competing Products

13 competing products in BRAF V600E

See all competitors
ProductCompanyStageHype Score
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
TMZ + E7016EisaiPhase 2
27
Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-FluorouracilOno PharmaceuticalPhase 3
40
encorafenib + Binimetinib + CetuximabOno PharmaceuticalPhase 2
35
Tafinlar/MekinistNovartisPre-clinical
33
BKM120 Combined with Vemurafenib (PLX4032)NovartisPhase 1/2
32
Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + TislelizumabNovartisPhase 1
21
Cobimetinib + Atezolizumab + PembrolizumabRochePhase 3
32
LGX818 + MEK162 + LEE011PfizerPhase 1/2
32
MEK162PfizerPhase 2
35
Encorafenib + Binimetinib + cemiplimab+fianlimabRegeneron PharmaceuticalsPhase 2
42
Plixorafenib + Cobicistat 150 MG [Tybost]Brain BiotechPhase 1
26
Dabrafenib + Trametinib + HydroxychloroquineBrain BiotechPhase 1/2
26